Mayo team spot­lights the role of senes­cent cells in neu­rode­gen­er­a­tion, start­ing down a path­way that may lead to Alzheimer’s

As an­ti-ag­ing re­search grows around the world, there’s been a big fo­cus on clear­ing away the “senes­cent” cells that clut­ter bod­ies as peo­ple grow old­er. These ag­ing cells lose the abil­i­ty to di­vide and mouse stud­ies have of­fered a pre­clin­i­cal the­o­ry that sweep­ing them away with new drugs can of­fer peo­ple longer, health­i­er lives.

Now a re­search team at the Mayo Clin­ic is of­fer­ing more an­i­mal da­ta to back that up, and they’re shin­ing a light on a new path­way in neu­rode­gen­er­a­tion and specif­i­cal­ly Parkin­son’s and Alzheimer’s — per­haps the sin­gle most frus­trat­ing field in drug de­vel­op­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.